Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease

Abstract

The development of vaccines to prevent SARS-CoV-2 infection has mainly relied on the induction of neutralizing antibodies (nAbs) to the Spike protein of SARS-CoV-2, but there is growing evidence that T cell immune response can contribute to protection as well. In this study, an anti-receptor binding domain (RBD) antibody assay and an INFγ-release assay (IGRA) were used to detect humoral and cellular responses to the Pfizer-BioNTech BNT162b2 vaccine in three separate cohorts of COVID-19-naïve patients: 108 healthcare workers (HCWs), 15 elderly people, and 5 autoimmune patients treated with immunosuppressive agents. After the second dose of vaccine, the mean values of anti-RBD antibodies (Abs) and INFγ were 123.33 U/mL (range 27.55–464) and 1513 mIU/mL (range 145–2500) in HCWs and 210.7 U/mL (range 3–500) and 1167 mIU/mL (range 83–2500) in elderly people. No correlations between age and immune status were observed. On the contrary, a weak but significant positive correlation was found between INFγ and anti-RBD Abs values ( rho = 0.354, p = 0.003). As to the autoimmune cohort, anti-RBD Abs were not detected in the two patients with absent peripheral CD19 + B cells, despite high INFγ levels being observed in all 5 patients after vaccination. Even though the clinical relevance of T cell response has not yet been established as a correlate of vaccine-induced protection, IGRA testing has showed optimal sensitivity and specificity to define vaccine responders, even in patients lacking a cognate antibody response to the vaccine.

Vaccinated Patients Admitted in ICU with Severe Pneumonia Due to SARS-CoV-2: A Multicenter Pilot Study

“…The main limitations of the study are that we have not followed up on patients, most patients are still admitted to the ICU, and the short recruitment time of the study. Determination of antibody levels is not part of a routine procedure in hospitalized patients and therefore was not available in a small part of the sample, and we have also been able to observe that having adequate levels does not always ensure not developing the disease, considering the importance that other immunological mechanisms such as cellular immunity occupy in the pathophysiology of this disease [17]. We observed that the first dose of vaccination does not prevent the development of severe forms of the disease, supporting to maximize vaccine uptake with two doses among vulnerable populations.…”

B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications

“…Data on specific anti-Spike (S) antibody production and their protective role in vaccinated subjects are accumulating, while little is known on the T-cell response after vaccination, especially in immunosuppressed subjects ( 4 ).…”

A Rapid and Simple Multiparameter Assay to Quantify Spike-Specific CD4 and CD8 T Cells after SARS-CoV-2 Vaccination: A Preliminary Report

“…Some attempts have been made in this direction, also considering evaluating IFN-γ using IGRA tests [ 17 ]. However, the T cells’ response is expressed through different activation pathways, and the evaluation of a single cytokine may not fully reflect the state of activation of this compartment.…”